The Latest Cardiac and Vascular News
MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2022. Q3 Results and Recent Highlights: Revenue of $2.1 million in the third quarter […]
Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C., Nov. 08, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the third quarter ended September 30, 2022. The Company will host a webcast and conference call at […]
Salt Lake City, UT, Nov. 08, 2022 (GLOBE NEWSWIRE) — A new study by researchers at Intermountain Healthcare in Salt Lake City finds that patients without standard modifiable heart risk factors who experience a heart attack are common and more likely to fare better than heart-attack patients with known risk […]
– Voyager’s TRACERTM capsid platform validated by Pfizer option exercise – – Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER – – Pipeline programs advancing; development candidate selections for lead programs expected Q4 2022 to H1 2023 – – Conference call at 8:30 a.m. ET today – […]
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings Inc (NASDAQ: CDIO) today announced that it is sponsoring Becker’s Hospital Review 11th Annual Meeting, “The CEO + CFO Roundtable.” The conference is taking place this week, November 7-10, 2022, at the Hyatt Regency Hotel in Chicago. As part of Cardio Diagnostics’ sponsorship, Meesha Dogan, CEO, […]
– ARO-APOC3 decreased triglycerides by 86%, and non-HDL-C by 45% while increasing HDL-C by 99% in patients with severe hypertriglyceridemia – ARO-ANG3 decreased triglycerides by 59%, LDL-C by 32%, and was associated with a relative reduction in liver fat fraction in patients with mixed dyslipidemia – Olpasiran reduced lipoprotein(a) levels […]
Compiled Data from RADIANCE Global Program Show Consistent Treatment Effect and Safety Across Broad Patient Population PALO ALTO, Calif.–(BUSINESS WIRE)–ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. today announced consistent and significant blood pressure (“BP”) lowering results across a range of patients with uncontrolled hypertension, including across […]
Primary endpoint was not met for the modified intent-to-treat (mITT) population; however, clinical benefit observed in coronary artery bypass graft (CABG) patients Data showed relative risk reduction in specific study populations and overall lower rates of rehospitalization within 30 days compared to placebo Adverse Events (AEs) were numerically similar across […]
-RBT-1 interim results from a randomized double-blind placebo-controlled study showed statistically significant reductions in days on ventilator and days in ICU. 30-day hospital readmission was reduced by greater than 90% -(<0.0027)- -RBT-1 was recently granted Fast Track Designation from U.S. FDA- -Pivotal Phase 3 study of RBT-1 to be initiated […]
SAN DIEGO, Nov. 7, 2022 /PRNewswire/ — NovoMedix, LLC (“NovoMedix”), a biotechnology company developing novel, multi-pathway modulators for fibrosis and cancer, today announced the presentation of new preclinical data on NMX2 at the 2022 American Heart Association Scientific Session, being held November 5-7, 2022 in Chicago, Illinois. The presentation is titled, “Dual AMPK Activator/mTOR Inhibitor […]
